Rescue of Pap-Mas in Systemic JIA Using Janus Kinase Inhibitors, Case Report and Systematic Review
Authors:
- Franck ZekreFZFranck Zekre
- Anita DuncanADAnita Duncan
- Audrey LaurentALAudrey Laurent
- Maud TusseauMTMaud Tusseau
- Rémi PescarmonaRPRémi Pescarmona
- Sophie Collardeau-FrachonSCSophie Collardeau-Frachon
- Camille OhlmannCOCamille Ohlmann
- Sébastien VielSVSébastien Viel
- Philippe ReixPRPhilippe Reix
- Sarah BenezechSBSarah Benezech
- Alexandre BelotABAlexandre Belot
Open Access
- 4 April 2023
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (7) , 2702
Abstract
Introduction: Biological disease-modifying anti-rheumatic drugs (bDMARDs) targeting interleukin (IL)-6 and IL-1β represent a steroid-sparing first-line therapy used in systemic-onset juvenile idiopathic arthritis (sJIA). Recently, the occurrence of pulmonary alveolar proteinosis (PAP) in sJIA patients was reported with early-onset and exposure to bDMARDs as potential risk factors. We report on a new case with longitudinal immunomonitoring successfully treated by Janus Kinase inhibitors (JAKi) and review past clinical descriptions of this new entity. Methods: We report one case of pulmonary alveolar proteinosis and macrophage activation syndrome (PAP-MAS) with longitudinal immunomonitoring. We then conducted a review of the literature of seven publications reporting 107 cases of PAP-MAS sJIA, and included the main characteristics and evolution under treatment. Results: Of the seven articles analyzed, the incidence of PAP-MAS among sJIA patients varied from 1.28% to 12.9%. We report here a single case among a cohort of 537 sJIA patients followed in the pediatric department of the Hospices Civils de Lyon over the last 15 years. This child presented with all clinical and immunological characteristics of PAP-MAS. After several lines of treatment, he benefited from JAKi and improved with respect to both systemic symptoms and lung disease. In the literature, strategies with monoclonal antibodies targeting either INF-γ or IL-1β/IL-18 have been tested with variable results. Orally taken JAKi presents the advantage of targeting multiple cytokines and avoiding parenteral injections of monoclonal antibodies that may contribute to the pathogenesis. Conclusions: JAKi represent a promising option in the treatment of lung disease associated with sJIA.Keywords
Funding Information
- ANR (ANR-21-CE17-0064)
This publication has 34 references indexed in Scilit:
- Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritisAnnals of the Rheumatic Diseases, 2017
- Respiratory complications of the rheumatological diseases in childhoodArchives of Disease in Childhood, 2016
- Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseasesNature Reviews Rheumatology, 2015
- T-cell–restricted T-bet overexpression induces aberrant hematopoiesis of myeloid cells and impairs function of macrophages in the lungBlood, 2015
- Methotrexate‐Induced Pulmonary ToxicityCanadian Respiratory Journal, 2013
- Pulmonary Hypertension and Other Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic ArthritisArthritis Care & Research, 2012
- Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatmentGenes & Immunity, 2012
- Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questionsNature Reviews Rheumatology, 2011
- Thoracic Findings of Systemic Diseases at High-Resolution CT in ChildrenRadioGraphics, 2011
- GM-CSF Autoantibodies and Neutrophil Dysfunction in Pulmonary Alveolar ProteinosisNew England Journal of Medicine, 2007